Swiss Life Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Swiss Life Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$181K	Buy	+10,690	New	+$150K	﹤0.01%	1542

Other funds holding NTLA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CGH

Contrarius Group Holdings Hamilton, Bermuda $2.17B AUM 134.87% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Swiss Life Asset Management's NTLA Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 10,690 shares worth $181K. The stake represents ﹤0.01% of the portfolio and ranks #1542 among its holdings.

190 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Swiss Life Asset Management held 10,690 shares of Intellia Therapeutics worth $181K as of Q2 2026.
Intellia Therapeutics was a new Swiss Life Asset Management position in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1542 holding.
190 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.